Canada Pharmaceutical Industry

Abstract

The Canadian pharmaceutical market is the eighth largest in the world, accounting for about two percent of the world market by sales. Canada also has the fourth fastest growing pharmaceutical industry after China, the US and Spain and has shown a steady growth trend. The Canadian pharmaceutical industry is gradually becoming more favorable towards generic drugs rather than branded drugs. Pfizer is Canada' s leading pharmaceutical company and generic manufacturer Apotex is the country' s leading generic company, and the fifth largest pharmaceutical manufacturer.

Although the pharmaceutical industry claims to be a high-risk business, year after year drug companies enjoy higher profits than any other industry. The pharmaceutical industry is one of the most innovative and profitable industries in Canada. This industry is composed of brand-name drug companies (which include biopharmaceutical companies) and generic drug companies. Both segments produce prescription and non-prescription drugs

Aruvian' s R' search' s report - ‘Canada Pharmaceutical Industry’ - explores the Canadian Pharmaceutical Industry landscape from the basics to the issues facing the industry today. The report delves in to the TRIPS agreement and the effect of the agreement on the Canadian pharmaceutical industry, growth trends in the industry, competition in the industry, etc.

The report also analyzes the Canadian pharmaceutical industry through two frameworks - a SWOT analysis and a Porter' s Five Forces Business Strategy analysis. The report also looks at strategies for market entry, the role of R&D in the Canadian Pharmaceutical Industry, and the role of the government in the industry.

Complete with a comprehensive section on the clinical trials, market investment opportunities going on in the Canadian pharmaceutical industry, Aruvian' s latest research is a collection of all you need to know about Canada' s Pharmaceutical Industry.

Table of Contents

A. Executive Summary

B. Introduction to the Industry

• B.1 Industry Definition
• B.2 Canada' s Pharmaceutical Sector - SWOT Framework Analysis
• B.3 Industry Overview
• B.4 Size & Structure of the Industry
• B.5 Market Segments
• B.6 Canadian Drug Sales
• B.7 Competition in the Industry
• B.8 Leading Products in the Industry
• B.9 Major Growth Factors
• B.10 Canada' s Pharmaceutical Industry' s Cost Advantage
• B.11 Clinical Trials
• B.12 Market Access

C. OTC Pharmaceuticals in Canada

• C.1 Industry Definition
• C.2 Industry Overview
• C.3 Market Segments
• C.4 Market Share
• C.5 Competition in the Sector
• C.6 Distribution Channels
• C.7 Sector Forecast

D. Generics Market in Canada

• D.1 Industry Definition
• D.2 Industry Overview
• D.3 Market Segments
• D.4 Market Share
• D.5 Competition in the Sector
• D.6 Sector Forecast

E. Regulatory Developments & Trends in the Industry

F. Porter' s Five Forces Strategy Analysis of Canada' s Pharmaceutical Industry

• F.1 Bargaining Power of Buyers
• F.2 Bargaining Power of Suppliers
• F.3 Competitive Rivalry in the Industry
• F.4 Threat of New Entrants
• F.5 Threat of Substitutes
• F.6 Conclusion

G. Pricing and Reimbursement System in the Industry

H. Re-import Policies for Drugs

I. Pharmaceutical R&D in Canada

J. TRIPS & Canada

• J.1 The Doha Declaration
• J.2 Canadian Legislation
• J.3 Humanitarian Contributions of Canadian Companies
• J.4 Challenges in the Process

K. Industry Forecast

L. Major Industry Players

• L.1 Alpharma Inc.
• L.2 Apotex, Inc.
• L.3 AstraZeneca PLC
• L.4 Bristol-Myers Squibb Company
• L.5 GlaxoSmithKline Plc
• L.6 Johnson & Johnson
• L.7 Merck & Co., Inc.
• L.8 Novartis AG
• L.9 Pfizer Inc
• L.10 Teva Pharmaceutical Industries

M. Appendix

N. Glossary of Terms